Caribou Biosciences, Inc.
Caribou Biosciences develops CRISPR genome-edited CAR-T cell therapies for hematologic malignancies.
10-QNov 12Latest SEC filing
Nov 5Latest story
November 2026
October 2026
August 2026
Caribou Biosciences develops CRISPR genome-edited CAR-T cell therapies for hematologic malignancies.